Antibody, bispecific antibody and conjugate targeting folate receptor α (frα), and preparation and use thereof
By designing FRα dual epitope ADC antibodies, the problem that existing drugs cannot cover the population with intermediate and low FRα expression has been solved, achieving more efficient and safer ovarian cancer treatment and reducing drug side effects.
Patent Information
- Application Number
- PCT/CN2025/098911
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2025-06-04
- Publication Date
- 2025-12-11
AI Technical Summary
The existing FRα-targeting antibody-drug conjugate (IMGN853) cannot cover the larger population of FRα-moderate and low-expressing individuals in ovarian cancer treatment, and has safety issues such as poor bystander effect and ocular toxicity. There is a need to develop more effective and safer dual epitope ADC drugs.
An FRα dual-epitope ADC antibody was designed. It uses an antibody that specifically binds to FRα or its antigen-binding fragment, combined with a topoisomerase I inhibitor with side-killing activity. Through the design of specific heavy and light chain variable region amino acid sequences, an antibody conjugate with strong dual-epitope binding ability is formed.
It improved the treatment effect in patients with moderate to low FRα expression, reduced the bystander effect and ocular toxicity, and enhanced the efficacy and safety of ADC drugs.
Smart Images
Figure PCTCN2025098911-FTAPPB-I100001 
Figure PCTCN2025098911-FTAPPB-I100002 
Figure PCTCN2025098911-FTAPPB-I100003
Abstract
Citation Information
Patent Citations
Biparatome FR-alpha antibodies and immunoconjugates
CN114222756A
Antigen binding protein constructs and uses thereof
CN114786732A
Heavy chain antibody binding to folate receptor alpha
CN116615253A
Camptothecin derivative and ligand-drug conjugate thereof
WO2022078260A1
Antibody drug conjugate, and preparation method therefor and use thereof
WO2022253035A1